Steven Lehrer1, Peter H Rheinstein2, Kenneth E Rosenzweig2. 1. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States; Severn Health Solutions, Severna Park, MD, United States. Electronic address: steven.lehrer@mssm.edu. 2. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States; Severn Health Solutions, Severna Park, MD, United States.
Abstract
OBJECTIVES: Glioma susceptibility is inversely related to a history of allergies and atopy. Lung allergies are associated with 30% lower glioma susceptibility, compared to no lung allergies. Asthma and eczema also reduce the chance of glioma. However, the effect of allergy on glioma survival is not well characterized. Because of the allergy-glioma inverse relationship we examined the association of allergy with glioma survival in The Cancer Genome Atlas (TCGA). PATIENTS AND METHODS: We evaluated the association between allergy and overall survival in TCGA Glioma (LGG) dataset. In order to have a sample of sufficient size to analyze, we classified as allergic any patient who answered yes to any of the manifestations of allergy that were queried. RESULTS: We analyzed data from 526 patients with glioma. History of allergy conferred a survival advantage on glioma patients, when stratified by tumor histologic grade (p = 0.049). Because allergy confers a favorable prognosis, we performed Cox regression. The effect of allergy on survival was significant (p = 0.025, HR 0.525, 95% CI 0.299-0.924), independent of the effect of chromosome 1p (p < 0.001, HR 93.4, 95% CI 16-546) and 19q (p = 0.801, HR 1.2, 95% CI 0.23-6.9) codeletion or TP53 mutation (p = 0.015, HR 2.7, 95% CI 1.2-5.9), unrelated to TERT expression (p = 0.365, HR 1.1, 95% CI 0.89-1.4) or ATRX mutation (p = 0.904, HR 1.04, 95% CI 0.51-2.14), independent of tumor grade (grade 2 versus grade 3, p = 0.004, HR 2.2, 95% CI 1.3-3.8), not independent of histology (oligodendroglioma and oligoastrocytoma, NOS versus astrocytoma, p = 0.08, HR 0.62, 95% CI 0.36-1.1). Diminished RNA expression of three loci, having reproducible genetic associations with allergic disease risk, are significantly associated with increased survival in glioma: FOSL2, APOBR, and NCF4. Diminished NCF4 copy number is significantly associated with reduced survival (D). CONCLUSION: Our finding of the improved prognosis that allergy confers on glioma increases the potential importance of understanding the allergy-glioma inverse association. If the mechanism could be more clearly elucidated, new, more effective treatments and preventive measures may be developed. Further studies are warranted.
OBJECTIVES:Glioma susceptibility is inversely related to a history of allergies and atopy. Lung allergies are associated with 30% lower glioma susceptibility, compared to no lung allergies. Asthma and eczema also reduce the chance of glioma. However, the effect of allergy on glioma survival is not well characterized. Because of the allergy-glioma inverse relationship we examined the association of allergy with glioma survival in The Cancer Genome Atlas (TCGA). PATIENTS AND METHODS: We evaluated the association between allergy and overall survival in TCGA Glioma (LGG) dataset. In order to have a sample of sufficient size to analyze, we classified as allergic any patient who answered yes to any of the manifestations of allergy that were queried. RESULTS: We analyzed data from 526 patients with glioma. History of allergy conferred a survival advantage on gliomapatients, when stratified by tumor histologic grade (p = 0.049). Because allergy confers a favorable prognosis, we performed Cox regression. The effect of allergy on survival was significant (p = 0.025, HR 0.525, 95% CI 0.299-0.924), independent of the effect of chromosome 1p (p < 0.001, HR 93.4, 95% CI 16-546) and 19q (p = 0.801, HR 1.2, 95% CI 0.23-6.9) codeletion or TP53 mutation (p = 0.015, HR 2.7, 95% CI 1.2-5.9), unrelated to TERT expression (p = 0.365, HR 1.1, 95% CI 0.89-1.4) or ATRX mutation (p = 0.904, HR 1.04, 95% CI 0.51-2.14), independent of tumor grade (grade 2 versus grade 3, p = 0.004, HR 2.2, 95% CI 1.3-3.8), not independent of histology (oligodendroglioma and oligoastrocytoma, NOS versus astrocytoma, p = 0.08, HR 0.62, 95% CI 0.36-1.1). Diminished RNA expression of three loci, having reproducible genetic associations with allergic disease risk, are significantly associated with increased survival in glioma: FOSL2, APOBR, and NCF4. Diminished NCF4 copy number is significantly associated with reduced survival (D). CONCLUSION: Our finding of the improved prognosis that allergy confers on glioma increases the potential importance of understanding the allergy-glioma inverse association. If the mechanism could be more clearly elucidated, new, more effective treatments and preventive measures may be developed. Further studies are warranted.
Authors: E Susan Amirian; Renke Zhou; Margaret R Wrensch; Sara H Olson; Michael E Scheurer; Dora Il'yasova; Daniel Lachance; Georgina N Armstrong; Lucie S McCoy; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Jonine L Bernstein; Ryan T Merrell; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Beatrice S Melin; Melissa L Bondy Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254
Authors: Daniel H Lachance; Ping Yang; Derek R Johnson; Paul A Decker; Thomas M Kollmeyer; Lucie S McCoy; Terri Rice; Yuanyuan Xiao; Francis Ali-Osman; Frances Wang; Shawn M Stoddard; Debra J Sprau; Matthew L Kosel; John K Wiencke; Joseph L Wiemels; Joseph S Patoka; Faith Davis; Bridget McCarthy; Amanda L Rynearson; Joel B Worra; Brooke L Fridley; Brian Patrick O'Neill; Jan C Buckner; Dora Il'yasova; Robert B Jenkins; Margaret R Wrensch Journal: Am J Epidemiol Date: 2011-07-08 Impact factor: 4.897
Authors: Margaret Wrensch; John K Wiencke; Joe Wiemels; Rei Miike; Joe Patoka; Michelle Moghadassi; Alex McMillan; Karl T Kelsey; Kenneth Aldape; Kathleen R Lamborn; Andrew T Parsa; Jennette D Sison; Michael D Prados Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak Journal: Cell Date: 2016-01-28 Impact factor: 41.582
Authors: Judith Schwartzbaum; Bo Ding; Tom Borge Johannesen; Liv T N Osnes; Linda Karavodin; Anders Ahlbom; Maria Feychting; Tom K Grimsrud Journal: J Natl Cancer Inst Date: 2012-08-01 Impact factor: 13.506
Authors: Jeanette E Eckel-Passow; Kristen L Drucker; Thomas M Kollmeyer; Matt L Kosel; Paul A Decker; Annette M Molinaro; Terri Rice; Corinne E Praska; Lauren Clark; Alissa Caron; Alexej Abyzov; Anthony Batzler; Jun S Song; Melike Pekmezci; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Joseph Wiemels; John K Wiencke; Stephen Francis; Terry C Burns; Caterina Giannini; Daniel H Lachance; Margaret Wrensch; Robert B Jenkins Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Matthew T Carr; Camille J Hochheimer; Andrew K Rock; Alper Dincer; Lakshmi Ravindra; Fan Lily Zhang; Charles F Opalak; Nora Poulos; Adam P Sima; William C Broaddus Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379